Cary Street Partners’s Larimar Therapeutics LRMR Stock Holding History

Cary Street Partners’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$259K	Buy	+85,000	New	+$338K	0.01%	850

Other funds holding LRMR

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Next Level Private Harrison, New York $511M AUM 30.94% 1-Year Est. Return

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

Cary Street Partners's LRMR Position: Q2 2026 in Review

Cary Street Partners opened a new position in Larimar Therapeutics (LRMR) in Q2 2026: 85,000 shares worth $259K. The stake represents 0.01% of the portfolio and ranks #850 among its holdings.

11 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Cary Street Partners held 85,000 shares of Larimar Therapeutics worth $259K as of Q2 2026.
Larimar Therapeutics was a new Cary Street Partners position in Q2 2026.
Larimar Therapeutics made up 0.01% of Cary Street Partners's portfolio in Q2 2026, its #850 holding.
11 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.